



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

01 Mar 2016 (#7)

[\[Click on blue hyperlink for further information\]](#)

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Please be advised that you **must contact the Manager of Research Grants Management Office (RGMO)** (Eugene Baugaard eugeneb@sun.ac.za) **as soon as possible to inform of your intent to apply and then confirm at least 30 days before the submission date**. The NIH grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.**

Important notices

- Notice of Correction of AIDS Application Due Date in PAR-16-093 "Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R01)" ([NOT-OD-16-069](#)) and PAR-16-094 (R21) ([NOT-OD-16-070](#))
- Requirement for the Appropriate Signatures on NIH Forms and Official Documentation ([NOT-OD-16-071](#))
- Notice of Intent to Publish a Funding Opportunity Announcement for Investigator-Initiated Multi-Site Clinical Trials: Clinical Coordinating Center (UG3/UH3) ([NOT-HL-16-303](#))
- Notice of Intent to Publish a Funding Opportunity Announcement for Investigator-Initiated Multi-Site Clinical Trials: Data Coordinating Center (U24) ([NOT-HL-16-304](#))
- Participation by Danish Researchers in the NIH BRAIN Initiative ([NOT-MH-16-004](#))
- Notice of Availability of Administrative Supplements to NIMH-supported Research for FY2016 ([NOT-MH-16-005](#))

1. Pragmatic Strategies for Assessing Psychotherapy Quality in Practice

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(RFA-MH-17-500\)](#) **Type:** R01

Application Due Date: June 8, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This funding opportunity announcement (FOA) supports the development and testing of pragmatic strategies for assessing the quality of the delivery of psychosocial interventions (defined here as provider-delivered behavioral, cognitive, interpersonal or other psychosocial/psychotherapeutic approaches) for the treatment or prevention of mental health disorders. Specifically, the goal is develop assessment tools and strategies that are both psychometrically rigorous (i.e., reliable, valid and strongly predictive of therapy outcomes and associated with other "gold standard" metrics of quality) and pragmatic (i.e., feasible for use in community practice settings and useful for advancing efforts at training, supervision, quality monitoring, and/or quality improvement).

Budget: NIMH intends to commit \$2,500,000 in FY 2017 to fund 5-7 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years; however, applicants are strongly encouraged to limit the proposed project period to 3-4 years.

2. Small Vessel Vascular Contributions to Cognitive Impairment and Dementia (VCID) Biomarkers Development Projects

Letter of Intent due date: 30 days prior to the Application Due Date(s)

Hyperlink: [\(RFA-NS-16-020\)](#) **Type:** UH2/UH3

Application Due Date: May 10, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this funding opportunity announcement (FOA) is to support research that evaluates and further develops candidate predictive, diagnostic, target engagement and progression candidate biomarkers of small vessel cerebrovascular disease in human vascular contributions to cognitive impairment and dementia (VCID) and vascular/Alzheimer's mixed dementias. Biomarkers development projects funded under this FOA, with support from the Coordinating Center (RFA-NS-16-019), will: study biomarkers as individual projects and concurrently establish the interactive consortium (UH2, years 1-2); and then work together as a consortium to perform collaborative cross-project multi-disciplinary studies to further evaluate and develop the most promising biomarker candidates (UH3, years 3-5) to the point of being ready for large scale multi-site clinical validation studies including towards FDA qualification of small vessel VCID biomarkers for phase II and phase III clinical trials (to be carried out under future separate funding). This FOA is only for studies related to human biomarkers; animal or other disease model studies are not responsive to this FOA unless they directly inform like measures that are performed in parallel in humans; additionally, clinical trials are not responsive.

Budget: NINDS intends to commit up to \$5,000,000 in direct costs in FY2016 to fund 5-8 awards. Application budgets are limited to \$750,000 in direct costs per year, and must reflect the actual needs of the proposed project. The maximum project period is 5 years

3. Biomarkers for the Lewy Body Dementias

Letter of Intent due date: 30 days prior to the Application Due Date

Hyperlink: [\(RFA-NS-16-022\)](#) **Type:** U01

Application Due Date: May 10, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this funding opportunity announcement (FOA) is to 1) expand the collection of clinical data and biological specimens in the NINDS Parkinson's Disease Biomarkers Program (PDBP), a community research resource, to include data from patients with Lewy Body Dementias (including Dementia with Lewy Bodies and Parkinson's Disease with Dementia), and 2) to support hypothesis-driven clinical research to discover biomarkers that will improve the efficiency and outcome of Phase II clinical trials for the Lewy Body dementias and to provide an expansion of this existing research resource center for dissemination of information and access by the scientific community for further advancing research in this field. Applications may include both of these goals if justified.

Budget: NINDS intends to commit \$3,500,000 in FY 2016 to fund 5-7 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

4. Modelling of Infectious Disease Agent Study Research Projects

Letter of Intent due date: 30 days prior to the Application Due Date

Hyperlink: [\(PA-16-107\)](#) **Type:** R01

Application Due Date: [Standard dates](#) beginning on June 5, 2016 and [Standard AIDS dates](#) beginning May 7 2016 apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this funding opportunity announcement (FOA) is to support innovative research that will develop and apply computational tools and methods for modelling interactions between infectious agents and their hosts, disease spread, prediction systems and response strategies. The models should be useful to researchers, policymakers, or public health workers who want to better understand and respond to infectious diseases. This research opportunity encourages applications from institutions/organizations that propose to provide the scientific and public health communities better resources, knowledge, and tools to improve their ability to prepare for, identify, detect, control, and prevent the spread of infectious diseases caused by naturally occurring or intentionally released pathogens, including those relevant to biodefense.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

5. Spermatogenic Stem Cell Culture Systems to Preserve and Restore Reproductive Capacity in Males

Letter of Intent due date: 30 days prior to the Application Due Date

Hyperlink: [\(PAR-16-114\)](#) **Type:** R01

Application Due Date: June 5, 2016; June 5, 2017; June 5, 2018. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of spermatogenic stem cell (SSC) biology. The overarching goal is to increase the chances that couples may have biological offspring without using conventional assisted reproductive modalities (i.e., IVF, ICSI). A focal point of the initiative is on the development of new techniques to culture and expand these cells over an extended period of time. Another area of study includes methods to eliminate malignant cells from SSC cultures following chemotherapy/radiation treatment. Also, spermatogenic stem cells from human adults could have a major impact on drug development and toxicity testing as animal-based systems do not sufficiently mirror the situation in humans.

Budget: Application budgets are limited to \$300,000/yr (direct costs) and should reflect the actual needs of the proposed project. The maximum period of support is three years.



D71 - International Research Training Planning Grant: To plan for the preparation of an application for a D43 international research training grant or for a U2R international research training cooperative agreement.

D43 - International Research Training Grants: To support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

DP1 – NIH Director’s Pioneer Award (NDPA): To support individuals who have the potential to make extraordinary contributions to medical research. The NIH Director’s Pioneer Award is not renewable.

DP3 – Institutional Training and Director Program Projects -Type 1 Diabetes Targeted Research Award: To support research tackling major challenges in type 1 diabetes and promoting new approaches to these challenges by scientific teams.

P20 – Research Program Projects and Centers -Exploratory Grant: To support planning for new programs, expansion or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

R25 – NIH Education Projects: used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

R34 - Clinical Trial Planning Grant Program: To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U24 – Resource-Related Research Projects – Cooperative Agreements: To support research projects contributing to improvement of the capability of resources to serve biomedical research.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

UH2/UH3 – NIH Phase Innovation Awards Cooperative Agreement: To support the development of new research activities in categorical program areas. (Support generally is restricted in level of support and in time.) The UH3 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the UH2 mechanism. Although only UH2 awardees are generally eligible to apply for UH3 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under UH2.

U2R – International Research Training Cooperative Agreements: Cooperative agreement mechanism for D43 to support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

U19 - Research Program-Cooperative Agreements: supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective.

Glossary of selected acronyms:

FOA	Funding Opportunity Announcement
PA	Program Announcements (<i>click on “PA” to search for further funding opportunities</i>)
RFA	Request for Applications (<i>click on “RFA” to search for further funding opportunities</i>)

Complete [Glossary and acronym list of NIH Terms](#)